Overview and Scope
Toxoplasmosis treatment drugs refer to medications or pharmaceutical products that manage infectious diseases caused by Toxoplasma gondii. It is used to treat the parasitic infection that results from infection with a common parasite found in cat feces and contaminated food.
Sizing and Forecast
The toxoplasmosis treatment drugs market size has grown strongly in recent years. It will grow from $3.16 billion in 2023 to $3.36 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to limited treatment options, increased awareness of toxoplasmosis, growing prevalence of toxoplasmosis, expansion of healthcare infrastructure, evolving regulatory landscape.
The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.18 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to research and development investments, emerging therapies for toxoplasmosis, increasing healthcare expenditure, global initiatives for infectious disease control, adoption of personalized medicine approaches. Major trends in the forecast period include development of combination drug therapies, integration of precision medicine in treatment strategies, emphasis on early diagnosis and intervention, customized treatment regimens, advances in drug delivery methods.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/toxoplasmosis-treatment-drugs-global-market-report
Segmentation & Regional Insights
The toxoplasmosis treatment drugs market covered in this report is segmented –
1) By Drug Class: Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, Other Drug Class
2) By Indication: Chronic Toxoplasmosis Infection, Acute Toxoplasmosis Infection
3) By Route of Administration: Parenteral, Oral
4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
North America was the largest region in the toxoplasmosis treatment drugs market in 2023. The regions covered in the toxoplasmosis treatment drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12214&type=smpMajor Driver Impacting
Market Growth
The rising prevalence of toxoplasmosis infections is expected to propel the growth of the toxoplasmosis treatment drug market going forward. Toxoplasmosis is a generic term for infection and sickness brought on by the protozoan parasite Toxoplasma gondii in humans and animals. Toxoplasmosis infection increases the need for pyrimethamine, spiramycin, and leucovorin drugs used to treat patients with a particular type of toxoplasmosis, which boosts the toxoplasmosis treatment drug market. For instance, in August 2021, according to the Centers for Disease Control and Prevention, a US-based national public health agency, the global incidence and burden of disease for congenital toxoplasmosis were estimated to be 190,100 (95% CI 179,300-206,300) cases per year, corresponding to an incidence rate of 1.5 cases/1,000 live births and a burden of disease of 1.2 million disease-adjusted life years (DALYs) per year. Therefore, the rising prevalence of toxoplasmosis infections drives the toxoplasmosis treatment drug market.
Key Industry Players
Major companies operating in the toxoplasmosis treatment drugs market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca plc, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Ltd., Alvogen Group Inc, Manus Aktteva Biopharma LLP
The toxoplasmosis treatment drugs market report table of contents includes:
1. Executive Summary
2. Toxoplasmosis Treatment Drugs Market Characteristics
3. Toxoplasmosis Treatment Drugs Market Trends And Strategies
4. Toxoplasmosis Treatment Drugs Market – Macro Economic Scenario
5. Global Toxoplasmosis Treatment Drugs Market Size and Growth
.
.
.
32. Global Toxoplasmosis Treatment Drugs Market Competitive Benchmarking
33. Global Toxoplasmosis Treatment Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Toxoplasmosis Treatment Drugs Market
35. Toxoplasmosis Treatment Drugs Market Future Outlook and Potential Analysis
36. Appendix
Explore the trending research reports from TBRC:
https://topprnews.com/biopharmaceutical-fermentation-systems-market-forecast/
https://topprnews.com/chronic-wound-care-market-outlook/
https://topprnews.com/digital-audio-workstation-daw-software-market-trends/
https://goodprnews.com/biopharmaceutical-fermentation-systems-market-analysis/
https://goodprnews.com/chronic-wound-care-market-growth/
https://goodprnews.com/digital-audio-workstation-daw-software-market-forecast/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
